Genetically determined individual differences in the ability of oxidation of certain drugs have raised recently a considerable interest in view of their clinical importance. Determination of oxidation phenotype is used to obtain the best results of pharmacotherapy and to explain a lower efficiency of some drugs in particular patients. It has also been proved that the frequency of drugs side effects occurance and predisposition to some disease may depend on oxidation phenotype. In addition, investigation of oxidation polymorphism is used in pharmacotherapy in the prevention of drugs interactions.

The aim of the study was to identify the oxidation phenotype in a Polish population. The oxidation phenotype was determined with dextrometorphan (DM) as the indicatory drug. The study included 104 healthy Polish volunteers. DM (40 mg) was given orally to healthy adults and 10-hour urine samples were collected. DM and the metabolite dextrorphan (DT) were analysed by the HPLC methods. Phenotyping was performed using the metabolic ratio (MR) calculated as:

MR = 0-10 h urinary output of DM/ 0-10 h urinary output of DT.

Taking into consideration the metabolic ratio we can distinguish extensive (EM) and poor (PM) metabolizers in human population. Studies of populations indicate that 3-10% of Caucasian breed represents the slow oxidation phenotype (PM).
In our studies of the Polish population the frequency of slow oxidation phenotype is similar to the results in other European populations.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/6531 must be provided.

1. GENETIC DETERMINANTS IN ISCHAEMIC HEART DISEASE